Press Releases
Feb. 14, 2026
Ilham Aliyev met with President of Bulgaria in Munich
Gov't Institution
President of Azerbaijan
Owner: Azerbaijani Government
Feb. 9, 2026
Truck1 Media Partnership to Amplify Reach of AGRA 2026 in Bulgaria
Neutral
EIN Presswire
Jan. 30, 2026
U.S. Law Enforcement Assists Bulgarian Law Enforcement in Taking Down Three of the Largest Piracy Sites in The European Union
Gov't Institution
The U.S. Attorney's Office District of Puerto Rico
Owner: American Government
Feb. 26, 2026
Annual Accounts 2025
Gov't Institution
ECB - European Central Bank
Owner: European Union
Feb. 26, 2026
AU10TIX Enters a New Phase to Support Enterprises Navigating Risk and Regulatory Complexity
Indeterminate
GlobeNewswire, Inc.
Feb. 24, 2026
CRIMSON GLORY Announce their First New Album in 26 Years 'Chasing The Hydra'
Neutral
EIN Presswire
Feb. 17, 2026
New Diploma Release – Aircraft CAMO & AMO Technical Records Learning Path Diploma Launched by Sofema Online
Neutral
EIN Presswire
Feb. 17, 2026
'Amazing Days Anthem' arrives to unite Amazon sellers at Amazing Days Summit Sofia
Neutral
EIN Presswire
Feb. 19, 2026
Euro area monthly balance of payments: December 2025
Gov't Institution
ECB - European Central Bank
Owner: European Union
Feb. 19, 2026
Sigma CVM Romania Announces Alexandru Predut as New Country Manager
Neutral
EIN Presswire
Feb. 18, 2026
Unusual specialists with contradicting requirements: Phototrophic Acidobacteria
Neutral
EIN Presswire
Feb. 17, 2026
WMF 2026 Startup Competition is back, offering global exposure and $1M Startup World Cup access
Neutral
EIN Presswire
Feb. 17, 2026
ITS connects Kyrgyz broker Royal Pure Gold as its 20th broker partner and continues its global expansion
Indeterminate
GlobeNewswire, Inc.
Feb. 11, 2026
Helsinn and MagnaPharm enter long-term agreement for AKYNZEO® and ALOXI® across five Central and Eastern European countries
Indeterminate
GlobeNewswire, Inc.
Feb. 11, 2026
Parabellum Investments sells BPO leader Parseq to Paragon Group
Neutral
EIN Presswire
Feb. 11, 2026
Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
Indeterminate
GlobeNewswire, Inc.